Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 22 May 2019
Price : $35 *
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 20 May 2019 Planned End Date changed from 9 Mar 2021 to 8 Mar 2020.
- 20 May 2019 Planned primary completion date changed from 9 Mar 2021 to 8 Mar 2020.
- 20 May 2019 Status changed from recruiting to active, no longer recruiting.